Allogene Therapeutics ALLO Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's common stock, par value (in dollars per share)?
- Allogene Therapeutics (ALLO) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
- How has Allogene Therapeutics's common stock, par value (in dollars per share) changed year-over-year?
- Allogene Therapeutics's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Allogene Therapeutics's common stock, par value (in dollars per share)?
- Over 5 years (2020 to 2025), Allogene Therapeutics's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.